Clinical trials: irinotecan hydrochloride, completed
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places…
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03641313
- Testing
- Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy
- Where
- 31 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Rectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer
This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced rectal cancer
- Trial name
- NCT03443661
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Aiping Zhou
Metastatic Colorectal Cancer
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients
- Trial name
- NCT01437618
- Testing
- FOLFOXIRI plus bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Metastatic Colorectal Cancer
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.
- Trial name
- AtezoTRIBE (NCT03721653)
- Testing
- Bevacizumab, Irinotecan, Oxaliplatin
- Where
- Italy
- Volunteers
- 218 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.
- Trial name
- MACBETH (NCT02295930)
- Testing
- folfoxiri+cetuximab+surgery+cetuximab, folfoxiri+cetuximab+surgery+bevacizumab
- Where
- 22 sites in Italy
- Volunteers
- 143 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003711
- Testing
- irinotecan hydrochloride, pemetrexed disodium
- Where
- 2 sites in United States
- Sponsor
- San Antonio Cancer Institute
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- FOLFERA (NCT01205711)
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 4 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Cardiff University
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.
- Trial name
- NCT05630183
- Testing
- Botensilimab, Gemcitabine, Nab-paclitaxel
- Where
- 36 sites in United States
- Volunteers
- 81 people
- Sponsor
- Agenus Inc.
Colorectal Cancer
Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006366
- Testing
- fluorouracil, irinotecan hydrochloride, conventional surgery
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Gastric Cancer
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
The purpose of this study is compare overall survival of the test arm (CPT-11/S-1 combination) to the control arm (CPT-11 alone) in the subjects with S-1 refractory advanced gastric cancer.
- Trial name
- NCT00639327
- Testing
- S-1 + irinotecan, irinotecan
- Where
- 86 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Japan Clinical Cancer Research Organization
Metastatic Colorectal Adenocarcinoma
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
To evaluate tolerance to and efficacy of bevacizumab in the treatment of MCRC in elderly patients, we propose a phase II randomised study comparing a chemotherapy + bevacizumab arm with a chemotherapy alone arm in the first-line…
- Trial name
- Prodige20 (NCT01900717)
- Testing
- LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified, LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Biliary Tract Cancer
Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.
- Trial name
- NCT00832689
- Testing
- Irinotecan and Gemcitabine
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Yonsei University
Colorectal Cancer
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers.
- Trial name
- NCT00559676
- Testing
- capecitabine, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospital Regional Universitaire de Limoges
Lymphoma, Small Intestine Cancer
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with abnormal liver or kidney function or who have received…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003368
- Testing
- irinotecan hydrochloride
- Where
- 45 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
- Trial name
- NCT03797625
- Testing
- Irinotecan, DDP, Endostar
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Colorectal Cancer
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00020917
- Testing
- cetuximab, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
Phase II trial to study the effectiveness of the monoclonal antibody trastuzumab and chemotherapy with irinotecan in treating patients who have stage IV colorectal cancer that overexpresses HER2.
- Trial name
- NCT00003995
- Testing
- trastuzumab, irinotecan hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Chemotherapy Effect
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors…
- Conditions
- Metastatic Colorectal Cancer, Chemotherapy Effect, Biomarker
- Trial name
- NCT03532711
- Testing
- fluorouracil
- Volunteers
- 264 people
- Sponsor
- Fudan University